Vancomycin Research History: Discovery, Key Trials and Regulatory Timeline

Vancomycin is a prescription medicine in the glycopeptide antibiotic class. Its published history spans more than six decades, from a soil-screening programme in the 1950s through the resistance epidemiology of the 1990s and 2000s to modern pharmacokinetic monitoring studies. This page sets out what the peer-reviewed literature reports, in chronological order, with the PubMed citation beside each claim. This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician with any question about whether a medicine is appropriate for a particular person.

Discovery: who, when and from what source

A 2006 historical review published in Clinical Infectious Diseases traced vancomycin's development to the 1950s, when pharmaceutical soil-screening programmes were searching for agents active against penicillin-resistant staphylococci, and reported that the compound was isolated from an actinomycete recovered from a soil sample originating in Borneo (PMID 16323120). That same review reported that the producing organism was originally designated Streptomyces orientalis and that the experimental compound was carried under a laboratory code number before receiving its generic name, which was derived from the word "vanquish" (PMID 16323120).

A 2014 review of the glycopeptide class in The Journal of Antibiotics reported that the vancomycin-producing organism is now classified as Amycolatopsis orientalis, and placed vancomycin as the founding member of a family that later included teicoplanin and the semisynthetic lipoglycopeptides (PMID 25118105). Researchers in that review described the shared glycopeptide mechanism of binding the D-alanyl-D-alanine terminus of peptidoglycan precursors, thereby blocking cell-wall cross-linking in Gram-positive bacteria (PMID 25118105).

The "Mississippi mud" preparations

The 2006 history reported that the earliest clinical preparations were impure and brown in colour, earning the nickname "Mississippi mud", and that a substantial part of the drug's early toxicity reputation was attributed in the literature to those impurities rather than to the purified molecule (PMID 16323120). A 2008 review in the Southern Medical Journal likewise revisited this early period when examining how the agent's past shaped later prescribing debates (PMID 18364659).

Regulatory timeline as published

The 2006 historical review reported that vancomycin was approved by the US Food and Drug Administration in 1958, at a time when penicillin-resistant Staphylococcus aureus was spreading in hospitals (PMID 16323120). The same review reported that use fell away after the semisynthetic penicillins became available, and rose again decades later when methicillin-resistant S. aureus, coagulase-negative staphylococci and Clostridium difficile colitis became common hospital problems (PMID 16323120).

The early clinical era: 1950s to 1970s

The published record of vancomycin's first two decades is dominated by clinical experience and observational description rather than the large randomised designs that became standard later; the 2006 history characterised the agent's introduction as a direct response to penicillin-resistant staphylococcal disease and reported that its role narrowed once semisynthetic penicillins arrived (PMID 16323120). A 2008 review revisited this period and argued that understanding the drug's early history was relevant to contemporary stewardship debates about preserving its usefulness (PMID 18364659).

The MRSA era and renewed interest: 1980s

According to the 2006 historical review, vancomycin consumption increased markedly in the 1980s as methicillin-resistant S. aureus, infections of implanted devices and antibiotic-associated colitis became prominent, and the review reported that this rise in use preceded the resistance problems that followed (PMID 16323120). The 2008 review in the Southern Medical Journal framed the same decade as the point at which the agent moved from a reserve option to a hospital workhorse, and discussed the implications researchers drew for future resistance (PMID 18364659).

Resistance: what the studies reported

Vancomycin-resistant enterococci

A 2001 Japanese review of vancomycin-resistant enterococci summarised the recognition and spread of VRE as a nosocomial problem and described the van gene clusters underlying the phenotype (PMID 11304988). A 2021 review in Infectious Disease Clinics of North America reported on VRE epidemiology, transmission and infection-prevention measures in healthcare settings, describing colonisation pressure and environmental contamination as recurring themes in outbreak investigations (PMID 34752227). A 2024 clinical overview of Enterococcus infections described the genus as an important cause of healthcare-associated infection and reviewed vancomycin resistance within that context (PMID 33620836).

Molecular mechanisms

A 2020 review in Protein Science reported that high-level vancomycin resistance arises when bacteria remodel the peptidoglycan precursor terminus from D-alanyl-D-alanine to D-alanyl-D-lactate or D-alanyl-D-serine, sharply reducing the binding affinity that underlies the antibiotic's activity (PMID 31899563). The study described the enzymes and two-component regulatory systems encoded by the van operons that carry out this substitution (PMID 31899563).

Reduced susceptibility in Staphylococcus aureus

A review of vancomycin-intermediate resistance in S. aureus reported that intermediate and heteroresistant strains are associated with thickened cell walls that sequester the drug before it reaches its target, a mechanism distinct from the van-mediated route seen in enterococci (PMID 27873679). A 2017 review in the Yale Journal of Biology and Medicine reported on fully vancomycin-resistant S. aureus, describing acquisition of enterococcal van determinants and noting that such isolates have remained rare compared with intermediate-resistance phenotypes (PMID 28656013).

Adverse Events: What Studies Report

The 2006 historical review reported that nephrotoxicity and ototoxicity dominated early concerns about vancomycin and that these effects were widely attributed in the literature to impurities present in the first preparations, with later purified formulations reassessed on that basis (PMID 16323120). The 2008 review discussed how this toxicity reputation shaped prescribing patterns and monitoring practices over subsequent decades (PMID 18364659). Safety questions about any individual are matters for a prescribing clinician, not for general reading.

Pharmacokinetic and monitoring literature

Modern research has focused on exposure measurement rather than on new indications. A 2024 study in Clinical Biochemistry examined dose optimisation and pharmacokinetic target attainment of vancomycin in children, and researchers reported on how measured exposures compared with the targets used in therapeutic drug monitoring programmes (PMID 38325652). No dosing figures are reproduced here; decisions about dose, monitoring and suitability belong with a licensed prescriber.

Successor agents in the published record

The 2014 glycopeptide review reported that structural modification of the natural glycopeptide scaffold produced semisynthetic derivatives designed to retain activity against organisms with reduced vancomycin susceptibility (PMID 25118105). Separately, a 2021 regulatory summary in Drugs reported the first approval of contezolid, an oxazolidinone developed for Gram-positive infections (PMID 34365606). In the preclinical literature, a 2020 paper reported synthesis and structure–activity relationship work on teixobactin, a compound of interest because it targets cell-wall precursors at a site distinct from the D-Ala-D-Ala terminus (PMID 31792983).

How to read this history

• The discovery narrative, the 1958 approval date and the "Mississippi mud" account all trace to the 2006 historical review (PMID 16323120).
• Resistance epidemiology is reported separately for enterococci (PMID 34752227) and staphylococci (PMID 27873679), with different mechanisms described in each.
• The biochemical explanation for high-level resistance rests on precursor remodelling as reviewed in 2020 (PMID 31899563).
• Contemporary research emphasis has shifted toward exposure measurement in specific populations (PMID 38325652).

Vancomycin is a prescription medicine whose availability, indications and labelling are set by national regulators. Any question about whether it is appropriate in a given situation is a clinical question for a prescribing clinician. For a broader overview of the molecule, its mechanism and the literature base, see the related vancomycin learn page.

References

• Vancomycin: a history (Clinical Infectious Diseases, 2006)
• Vancomycin: understanding its past and preserving its future (Southern Medical Journal, 2008)
• Glycopeptide antibiotics: back to the future (The Journal of Antibiotics, 2014)
• Molecular mechanisms of vancomycin resistance (Protein Science, 2020)
• Vancomycin-intermediate resistance in Staphylococcus aureus (Journal of Global Antimicrobial Resistance, 2014)
• Vancomycin Resistance in Staphylococcus aureus (Yale Journal of Biology and Medicine, 2017)
• [Vancomycin-resistant enterococci (VRE)] (Nihon Rinsho, 2001)
• Vancomycin-Resistant Enterococci: Epidemiology, Infection Prevention, and Control (Infectious Disease Clinics of North America, 2021)
• Enterococcus Infections (StatPearls, 2024)
• Dose optimization and target attainment of vancomycin in children (Clinical Biochemistry, 2024)
• Contezolid: First Approval (Drugs, 2021)
• Synthesis and structure-activity relationships of teixobactin (Annals of the New York Academy of Sciences, 2020)